Amgen Update on Presentation Materials for Webcast and Novavax Receives Positive Results from Pre-Clinical Studies of Influenza Vaccines
Amgen Update on Presentation Materials for Webcast and Novavax Receives Positive Results from Pre-Clinical Studies of Influenza Vaccines
City of Industry, CA --(www.FinancialNewsUSA.com)-- 07/20/2006 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Amgen (Nasdaq:AMGN), the world's largest biotechnology company, announced that as part of its efforts to continuously improve its investor communications, it intends to provide a slide presentation with its upcoming second quarter financial results conference call, scheduled for Thursday, July 20, 2006 at 2 p.m. Pacific Daylight Time. The slide presentation will be posted in the Investor section of the company's Web site (www.amgen.com/investors) in advance of the company's conference call. Nabi Biopharmaceuticals (Nasdaq: NABI) will announce second quarter 2006 financial results on Wednesday, July 26, 2006, after market close. The company will host a conference call and live webcast at 4:30 p.m. ET. The live webcast can be accessed at the Nabi Biopharmaceuticals website at http://www.nabi.com.
Novavax Inc. (Nasdaq: NVAX) said recently that it has received positive results from several pre-clinical studies relating to the company's pandemic and seasonal influenza vaccines, which are under development. Scientists at the University of Pittsburgh and the Southern Research Institute in Birmingham, Ala., have been collaborating with Novavax to test the company's virus-like particle (VLP) vaccines for various strains of influenza. Dutton Associates updates its coverage of NutraCea (OTCBB:NTRZ) maintaining its rating at Strong Buy with a target price of $1.80. The 10-page report by Dutton senior analyst Gerald F. LaKarnafeaux, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. On October 4, 2005, the merger of NutraCea and RiceX was completed. The benefits of the merger to NutraCea are substantial.
Biotech News
City of Industry, CA --(www.FinancialNewsUSA.com)-- 07/20/2006 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Amgen (Nasdaq:AMGN), the world's largest biotechnology company, announced that as part of its efforts to continuously improve its investor communications, it intends to provide a slide presentation with its upcoming second quarter financial results conference call, scheduled for Thursday, July 20, 2006 at 2 p.m. Pacific Daylight Time. The slide presentation will be posted in the Investor section of the company's Web site (www.amgen.com/investors) in advance of the company's conference call. Nabi Biopharmaceuticals (Nasdaq: NABI) will announce second quarter 2006 financial results on Wednesday, July 26, 2006, after market close. The company will host a conference call and live webcast at 4:30 p.m. ET. The live webcast can be accessed at the Nabi Biopharmaceuticals website at http://www.nabi.com.
Novavax Inc. (Nasdaq: NVAX) said recently that it has received positive results from several pre-clinical studies relating to the company's pandemic and seasonal influenza vaccines, which are under development. Scientists at the University of Pittsburgh and the Southern Research Institute in Birmingham, Ala., have been collaborating with Novavax to test the company's virus-like particle (VLP) vaccines for various strains of influenza. Dutton Associates updates its coverage of NutraCea (OTCBB:NTRZ) maintaining its rating at Strong Buy with a target price of $1.80. The 10-page report by Dutton senior analyst Gerald F. LaKarnafeaux, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. On October 4, 2005, the merger of NutraCea and RiceX was completed. The benefits of the merger to NutraCea are substantial.
Biotech News
posted by Famous Quotations - Amgen Update on Presentation Materials for Webcast and Novavax Receives Positive Results from Pre-Clinical Studies of Influenza Vaccines
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home